tiprankstipranks
Trending News
More News >
Scandion Oncology A/S (SE:SCOL)
:SCOL

Scandion Oncology A/S (SCOL) AI Stock Analysis

Compare
0 Followers

Top Page

SE

Scandion Oncology A/S

(Frankfurt:SCOL)

Rating:30Underperform
Price Target:
Scandion Oncology A/S faces significant financial and operational challenges typical of early-stage biotech companies. The lack of revenue and consistent losses are major concerns, compounded by reliance on external funding. Technical indicators suggest weak momentum, and the valuation is constrained by the negative P/E ratio due to ongoing losses. Overall, the stock is high-risk with uncertain prospects, primarily influenced by its financial health and market trends.

Scandion Oncology A/S (SCOL) vs. iShares MSCI Sweden ETF (EWD)

Scandion Oncology A/S Business Overview & Revenue Model

Company DescriptionScandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of chemotherapy resistance. Its lead product candidate includes the SCO-101, an oral compound that is in clinical Phase Ib and Phase II studies in cancer patients. The company's other product candidate is SCO-201, which is in preclinical trial for the treatment of solid tumors. Scandion Oncology A/S was founded in 2017 and is headquartered in Copenhagen, Denmark.
How the Company Makes MoneyScandion Oncology A/S makes money through the development and commercialization of its drug candidates aimed at reversing cancer drug resistance. The company's revenue model primarily involves research and development collaborations, licensing agreements, and potential milestone payments from pharmaceutical partners. These partnerships can include upfront payments, research funding, and royalties on the sales of successfully marketed drugs. Additionally, Scandion Oncology may receive governmental or institutional grants to support their innovative research efforts. As the company's drug candidates progress through clinical trials and achieve regulatory approvals, these financial streams become crucial in driving growth and sustaining operations.

Scandion Oncology A/S Financial Statement Overview

Summary
Income Statement
Balance Sheet
Cash Flow
Breakdown
TTMDec 2023Dec 2022Dec 2021Dec 2020Dec 2019
Income StatementTotal Revenue
0.000.000.000.000.00205.44K
Gross Profit
0.000.000.000.000.00-11.16M
EBIT
-38.31M-45.36M-80.17M-55.37M-22.89M-15.39M
EBITDA
-37.46M-45.53M-80.82M-56.10M-22.85M-15.60M
Net Income Common Stockholders
-32.47M-39.20M-76.70M-51.70M-16.27M-12.18M
Balance SheetCash, Cash Equivalents and Short-Term Investments
26.52M26.52M77.61M105.71M5.81M15.42M
Total Assets
34.56M34.56M89.40M116.22M186.41M19.90M
Total Debt
499.00K499.00K1.60M1.22M316.00K1.42K
Net Debt
-26.02M-26.02M-76.01M-104.49M-5.50M-15.42M
Total Liabilities
3.44M3.44M19.07M11.68M30.54M1.56M
Stockholders Equity
31.12M31.12M70.33M104.54M155.87M18.34M
Cash FlowFree Cash Flow
-35.72M-50.67M-69.86M-50.12M-17.50M-10.20M
Operating Cash Flow
-35.72M-50.67M-69.44M-49.80M-17.45M-9.96M
Investing Cash Flow
510.00K288.00K-389.00K-485.00K-46.00K-238.28K
Financing Cash Flow
13.69M-705.00K41.73M150.18M7.89M17.95M

Scandion Oncology A/S Technical Analysis

Technical Analysis Sentiment
Negative
Last Price0.02
Price Trends
50DMA
0.01
Positive
100DMA
0.03
Negative
200DMA
0.07
Negative
Market Momentum
MACD
<0.01
Positive
RSI
49.77
Neutral
STOCH
61.11
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:SCOL, the sentiment is Negative. The current price of 0.02 is above the 20-day moving average (MA) of 0.02, above the 50-day MA of 0.01, and below the 200-day MA of 0.07, indicating a neutral trend. The MACD of <0.01 indicates Positive momentum. The RSI at 49.77 is Neutral, neither overbought nor oversold. The STOCH value of 61.11 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:SCOL.

Scandion Oncology A/S Peers Comparison

Overall Rating
UnderperformOutperform
Sector (54)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
54
Neutral
$5.31B3.26-45.10%2.79%16.76%0.02%
30
Underperform
€4.46M-186.04%57.91%
DE5LD
€640.18K-107.11%
DE1XT
€27.89M
DE9RP
€5.11M-104.17%
€4.43M-47.01%
€4.03M-147.64%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
SE:SCOL
Scandion Oncology A/S
0.02
-0.37
-95.64%
DE:5LD
LIDDS AB
0.01
0.00
0.00%
DE:1XT
Xintela AB
0.03
0.02
200.00%
DE:9RP
Lipigon Pharmaceuticals AB
0.02
0.01
100.00%
DE:COJ0
CombiGene AB
0.17
-0.07
-29.17%
DE:5JA1
Sprint Bioscience AB
0.02
-0.08
-80.00%
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.